A Novel Prognostic Model for Malignant Mesothelioma Incorporating Quantitative FDG-PET Imaging with Clinical Parameters
Open Access
- 14 April 2010
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 16 (8) , 2409-2417
- https://doi.org/10.1158/1078-0432.ccr-09-2313
Abstract
Purpose: We have shown the feasibility of administering inhaled doxorubicin to patients with cancer. This study evaluated inhaled doxorubicin combined with cisplatin and docetaxel in patients with non–small cell lung cancer. The principal objective was to determine safety and, secondarily, efficacy.Keywords
This publication has 34 references indexed in Scilit:
- From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid TumorsJournal of Nuclear Medicine, 2009
- SmcHD1, containing a structural-maintenance-of-chromosomes hinge domain, has a critical role in X inactivationNature Genetics, 2008
- Validating a prognostic modelCancer, 2006
- Global Gene Expression Profiling of Pleural Mesotheliomas: Overexpression of Aurora Kinases and P16/CDKN2A Deletion as Prognostic Factors and Critical Evaluation of Microarray-Based Prognostic PredictionCancer Research, 2006
- Prognostic factors in mesotheliomaLung Cancer, 2005
- Consensus report: Pretreatment minimal staging and treatment of potentially resectable malignant pleural mesotheliomaLung Cancer, 2005
- Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implicationsThe Journal of Thoracic and Cardiovascular Surgery, 2005
- Serum PDGF-AB in Pleural MesotheliomaTumor Biology, 2005
- Post-hoc analysis of sodium bicarbonate use or EMS systems? A caveat in resuscitation researchActa Anaesthesiologica Scandinavica, 2005
- A proposed new International TNM Staging System for malignant pleural mesothelioma from the International Mesothelioma Interest GroupLung Cancer, 1996